Giuseppe Curigliano
Giuseppe Curigliano, MD, PhD, is the director of the Early Drug Development Division at the European Institute of Oncology, a comprehensive cancer centre in Milan, Italy. He is professor of Medical Oncology in the Department of Oncology and Haemato-Oncology at the University of Milan. In ESMO he served as Chair the ESMO Nomination Committee (2017-2019) and as Chair of the ESMO Clinical Practice Guidelines Committee (2019-2023). He was one of the founding members and served as scientific Co-Chair of the “ESMO Breast Cancer Congress”. He also served several years as scientific co-chair of the St Gallen Early Breast Consensus Conference. He contributed to launch the ESMO Living Guidelines and to the recognition of the Fellow of ESMO (FESMO). He organised and participated in many professional and educational congresses for oncologists all over the world. Professor Curigliano’s research focuses on biomarkers and personalised therapies, with an emphasis on biomarker discovery, targeted agent development, and the integration of personalised medicine. He leads Phase I-III clinical trials on targeted therapies for breast cancer and oversees large-scale national studies on the implementation of high-throughput technologies in healthcare systems. Professor Curigliano was identified as Clarivate™ world’s most influential researcher (the highly cited researchers) in 2022, 2023 and 2024. He has authored more than 900 papers in peer-reviewed journals (h-index 109) and many book chapters. He served as editorial board member for international oncology journals (European Journal of Oncology, Journal of Clinical Oncology, Annals of Oncology). He served as Editor in Chief of ESMO Open from 2022 to 2025. He trained, mentored and sponsored dozens of medical oncologists from Latin America, Africa, Asia and Italy. Professor Curigliano was awarded with the first ESO Umberto Veronesi Award (2017) and with the Fellowship of the European Academy of Cancer Sciences in Paris (2017). He is ESMO President Elect.